SCHEMBL6496145

SCHEMBL6496145

Fc1ccc2oc3ccc(NCc4cccc(F)c4F)cc3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
MAPT P10636 6/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
MEN1 O00255 3/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 3/20 0.42
CYP3A4 P08684 2/20 0.42
CYP1A2 P05177 2/20 0.42
ATM Q13315 1/20 0.42
PLA2G1B P04054 1/20 0.42
CYP2D6 P10635 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NTRK1 P04629 2/20 0.39
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 2/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481773 0.90 KMT2A (0.45) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6495652 0.89 MAPT (0.54) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6775567 0.88 KMT2A (0.44) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6494767 0.88 MAPT (0.42) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6768334 0.88 CYP3A4 (0.37) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6770100 0.87 KMT2A (0.49) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6494439 0.83 NTRK1 (0.40) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6768301 0.83 MEN1 (0.43) KMT2AMAPTL3MBTL1MEN1CYP2C9
SCHEMBL6775761 0.83 EGFR (0.44) KMT2AMAPTL3MBTL1MEN1ATM
SCHEMBL6482478 0.82 MAPT (0.40) KMT2AMAPTL3MBTL1MEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 KMT2A 412/4885MAPT 2337/4885L3MBTL1 3832/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 KMT2A 770/4885MAPT 3500/4885L3MBTL1 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.